Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
L-PPDS with Adjunctive Xalatan in Glaucoma/OH
NCT01037036Phase 2Completed
- Sponsor
- Mati Therapeutics
- Start
- Dec 2009
- Primary completion
- Apr 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of latanoprost ophthalmic solution 0.005% (TearClear TC-002) in ocular hypertension, open-angle glaucoma (OAG), sponsored by Mati Therapeutics. Started Dec 2009; status: completed.
02
Drugs
latanoprost ophthalmic solution 0.005% (TearClear TC-002)
03
Conditions
ocular hypertensionopen-angle glaucoma (OAG)
Beyond the preview
Go deeper on NCT01037036.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01037036.